{"filings":[{"id":899649,"accession_number":"0001762303-26-000011","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-06-05T23:25:40+00:00","items":["1.01","9.01"],"status":"ready","headline":"AVITA Medical issues warrant to Perceptive for 500,000 shares at $3.4019 after shareholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved warrant at June 3, 2026 Annual Meeting; warrant issued June 5.","Warrant covers 500,000 shares (plus 150,000 contingent) at $3.4019 exercise price.","Warrant issued to Perceptive under January 2026 $60M senior secured credit facility.","Warrant shares registered under Form S-3 (File 333-294790) and prospectus supplement filed June 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":842438,"accession_number":"0001762303-26-000003","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-06-03T23:19:36+00:00","items":["5.02","5.07"],"status":"ready","headline":"AVITA Medical shareholders approve director fee pool increase, equity grants, and warrant issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Non-executive director cash fee pool increased from $750K to $900K per annum.","Annual equity grants of 22,214 RSUs and 16,133 options approved for each of six non-executive directors.","Initial grants to Dr. Tarnoff: 26,250 RSUs + 19,063 options; to Joseph Woody: 40,547 RSUs + 29,446 options.","Warrants for up to 650,000 shares (10-year term) to Perceptive Credit Holdings approved.","Shareholders authorized additional 10% equity issuance capacity under ASX Listing Rule 7.1A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442678,"accession_number":"0001193125-26-224022","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-05-14T20:10:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.","Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.","Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.","Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.","Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95275,"accession_number":"0001193125-26-201662","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical appoints Cary Vance as permanent CEO, Jan Stern Reed as Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cary Vance named President and CEO effective April 30, 2026; served as Interim CEO since October 2025.","Jan Stern Reed appointed Chair of the Board; had been Lead Independent Director since October 2025.","Vance receives $702k base salary, 80% bonus target, and $3.354M in equity awards subject to stockholder approval.","Employment agreement: 3-year initial term; severance of 18 months base salary plus COBRA if terminated without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108208,"accession_number":"0001193125-26-048761","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).","Full-year 2025 revenue $71.6M (+11% YoY); net loss $48.6M ($1.74/sh) vs $61.8M ($2.39/sh) in 2024.","Net cash use improved to $5.1M in Q4; cash & marketable securities $18.2M at year-end.","New $60M credit facility with Perceptive Advisors; initial $50M funded, used to repay existing debt.","FY2026 revenue guidance $80-85M (12-19% growth); Cohealyx & PermeaDerm trials fully/significantly enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":71610000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108207,"accession_number":"0001193125-26-011167","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","3.02","9.01"],"status":"ready","headline":"AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.","FY2025 revenue $71.6M, up 11% YoY from $64.3M in 2024, within revised guidance.","FY2026 revenue guidance $80-85M (12-19% growth); TTM revenue covenant $68.5M for Q1 2026, $73M for FY2026.","New $60M credit facility with Perceptive Advisors ($50M funded, $10M option until Q1 2027); SOFR+7.5% (4% floor).","Warrant to purchase 500k shares (additional 150k if $10M drawn) at VWAP-based price; 10-year term; registration rights."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":71610000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108206,"accession_number":"0001193125-26-002418","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AVITA Medical appoints Joe Woody to board; Lou Panaccio retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joe Woody appointed non-executive director effective Jan 1, 2026; Lou Panaccio retires after 10+ years.","Woody recently served as CEO of Avanos Medical (2017-2024) and CEO of Acelity Holdings.","Annual cash retainer of $92,500; initial equity grant of $210,000 (30% options, 70% RSUs) subject to shareholder approval.","Woody to serve on all Board committees; independence determined by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124647,"accession_number":"0001193125-25-269535","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.","Full-year 2025 revenue guidance lowered to $70-74M from prior $76-81M, citing MAC reimbursement headwinds.","Sixth amendment to OrbiMed credit agreement adds $500K to principal, resets Q4 2025 revenue covenant to $70M.","RECELL GO received CE Mark under EU MDR; launch to begin in Germany, Italy, and UK.","Operating expenses down 24% YoY to $23.0M as part of cost discipline; cash $23.3M at Sept 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":53995000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124646,"accession_number":"0001193125-25-241705","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.","Board member Jan Reed appointed Lead Independent Director; search for permanent CEO commenced.","Preliminary Q3 2025 revenue expected ~$17M; company to provide update on Nov 6 earnings call.","OrbiMed waived Q3 2025 trailing 12-month net revenue covenant; discussions underway to redefine future covenants.","Departure not due to any disagreement with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141328,"accession_number":"0001762303-25-000026","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"AVITA Medical raises ~$15M via placement of 17.2M CDIs at AU$1.32 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 17.2M CHESS Depositary Interests (CDIs) at AU$1.32/CDI; 5 CDIs = 1 common share.","Expected net proceeds of ~$15M (A$22.7M) from Australian institutional/professional investors.","Placement agent fees ~$0.8M in cash and CDIs; transaction expected to close Aug 19, 2025.","Securities exempt from registration under Regulation S; not offered in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141327,"accession_number":"0001762303-25-000023","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical raises US$15M via Australian private placement at A$1.32/CDI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~US$15M (~A$23M) by issuing ~17.2M new CDIs at A$1.32 each (11% discount to last ASX close).","Placement supported by new and existing Australian institutional/professional investors.","Proceeds for working capital and strategic flexibility; expected to fund operations until free cash flow in 2026.","Settlement expected Aug 19, trading on ASX from Aug 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141326,"accession_number":"0001762303-25-000012","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"AVITA Medical Q2 revenue $18.4M (+21% YoY); slashes FY2025 revenue guidance to $76M-$81M, delays profitability to 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.","FY2025 revenue guidance reduced to $76M-$81M (prior $100M-$106M) due to MAC payment backlog affecting RECELL demand.","Fifth amendment to OrbiMed credit agreement: TTM revenue covenants lowered through Q2 2026; 400,000 common shares issued in lieu of cash fee.","Michael Tarnoff appointed to Board of Directors; adds healthcare leadership experience.","Clinical highlight: RECELL reduces hospital stays 36%; CMS NTAP approved for inpatient trauma wounds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":36932000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141325,"accession_number":"0000950170-25-104019","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AVITA Medical appoints Michael Tarnoff to Board; Cary Vance becomes Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Tarnoff appointed as non-executive Director, effective August 6, 2025; most recently Chief Physician Executive and CEO at Tufts Medical Center.","Tarnoff receives $70,000 annual cash retainer, initial equity grant of $210,000 (30% options, 70% RSUs); annual grants subject to shareholder approval.","Cary Vance elected Board Chair, succeeding Lou Panaccio after more than 10 years of service; effective August 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159140,"accession_number":"0000950170-25-081880","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AVITA Medical shareholders approve amended incentive plan, increase share reserve by 2.5M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended 2020 Omnibus Incentive Plan approved, increasing share reserve by 2.5M to 6.75M shares.","All seven director nominees elected; for-votes ranged from 8.6M to 10.0M across candidates.","Ratified Grant Thornton as independent auditor for FY2025 with 13.4M votes for.","Approved grants to each of six non-executive directors: 10,022 RSUs and 4,295 options each.","Approved grant of options to acquire 520,000 shares to CEO James Corbett."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159139,"accession_number":"0000950170-25-072746","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"AVITA Medical amends bylaws to align with updated Delaware law on shareholder meetings and electronic notice","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended and restated effective May 15, 2025, to reflect recent changes in applicable corporate law.","Updates pertain to conduct of stockholder meetings, electronic notice, and other procedural matters.","Full text of amended bylaws filed as Exhibit 3.1 with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159138,"accession_number":"0000950170-25-066911","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.","Gross profit margin 84.7%; RECELL-only margin 86.4%; expects ~$2.5M lower quarterly opex going forward.","Launched RECELL GO mini in Feb; nationwide Cohealyx launch on Apr 1 expanding addressable U.S. market to >$3.5B.","Obtained OrbiMed revenue covenant waiver for Q1; Q2 trailing 12-month covenant set at $78.0M.","Expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":18514000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177591,"accession_number":"0000950170-25-040249","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.","Revenue share for AVITA increases to 60% after manufacturing costs (was 50/50).","Stedical eligible for milestone payments tied to AVITA's achievement of sales targets.","Exclusive distribution agreement term extended to ten years from March 17, 2025.","PermeaDerm is FDA-cleared biosynthetic wound matrix; eligible for U.S. reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177590,"accession_number":"0000950170-25-019862","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.","Net loss $11.6M ($0.44 loss per share) vs $7.1M loss in Q4 2023.","FY2025 revenue guidance $100-106M (55-65% growth); expects GAAP profitability in Q4 2025.","Amended OrbiMed credit agreement; adjusted revenue covenants for 2025-2026; issued warrants for 145,180 shares at $0.01/share.","FDA clearances: Cohealyx (Dec 2024) and RECELL GO mini (Dec 2024); full Cohealyx launch by April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":64251000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177589,"accession_number":"0000950170-25-002907","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.","Full-year 2024 revenue now ~$64.3M (29% YoY growth) vs prior $68-70M.","FY 2025 revenue guidance $100-106M (55-65% growth).","Cashflow breakeven and GAAP profitability now expected in Q4 2025, delayed from Q3 2025.","Miss attributed to slower hospital year-end purchasing; new products RECELL GO and Cohealyx remain growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":64251000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194297,"accession_number":"0000950170-24-123279","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.","Net loss $16.2M ($0.62 loss per share) vs $8.7M loss in prior year quarter.","Amended OrbiMed credit agreement: terminated two $50M tranches, removed Q4 2024 revenue covenant.","Full-year 2024 revenue guidance reaffirmed at $68-70M (37-41% growth); Q4 guidance $22.3-24.3M.","Expects RECELL GO mini FDA approval by Dec 31, 2024; Cohealyx launch Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":45845000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210632,"accession_number":"0000950170-24-093941","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).","Net loss $15.4M ($0.60 loss per share) vs $10.4M loss ($0.41) in Q2 2023.","RECELL GO PMA approved May 29; RECELL GO mini submitted June 28, FDA decision by Dec 27.","Exclusive distribution deal with Regenity for dermal matrix; 510(k) clearance expected Q4 2024.","Q3 2024 revenue guidance $19-20M (40-48% YoY growth); FY24 guide revised to $68-70M (37-41% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":26299000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210631,"accession_number":"0000950170-24-088572","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AVITA Medical enters exclusive distribution deal for collagen dermal matrix with Regenity Biosciences","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.","AVITA to pay $2M upon 510(k) clearance, up to $3M more by Jan 4, 2026 contingent on clinical results.","Revenue sharing: 50% of avg sales price first 2 years, then 60% in subsequent years.","AVITA to commercialize under its brand in US, EU, Australia, Japan; clinical studies planned for 2025.","CEO Jim Corbett says collaboration strengthens portfolio and may establish new standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210630,"accession_number":"0000950170-24-079679","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical appoints Nicole Kelsey as Chief Legal & Compliance Officer; Donna Shiroma retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donna Shiroma retired as General Counsel effective June 28, 2024, succeeded by Nicole Kelsey.","Shiroma receives $453K severance, $113K prorated bonus, 12 months benefits, equity acceleration.","Shiroma entered a $40K one-month consulting agreement for transition services through July 31.","Kelsey previously Chief Legal Officer at Amyris and General Counsel at Criteo; will lead legal/compliance.","No disagreement cited; retirement was not caused by any disagreements with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228991,"accession_number":"0000950170-24-069945","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"AVITA Medical shareholders elect directors, approve equity awards at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Louis Panaccio, James Corbett, Jeremy Curnock Cook, Suzanne Crowe, Jan Stern Reed, Robert McNamara, Cary Vance.","Stockholders approved RSUs valued at $87,500 and options valued at $37,500 for each non-executive director.","CEO James Corbett granted options to acquire 350,000 shares of common stock, approved by shareholders.","Non-binding advisory vote on named executive officer compensation passed (10,269,125 for, 2,296,661 against).","Ratification of Grant Thornton LLP as independent auditor for FY2024 approved (14,794,234 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228990,"accession_number":"0000950170-24-066656","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.","Device reduces training burden, improves OR workflow, and controls enzyme incubation for optimal cell yield; launch June 2024.","Clinical benefits: uses less donor skin, reduces pain, speeds closure, cuts procedures, shortens hospital stays for burns <50% TBSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228989,"accession_number":"0000950170-24-058618","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.","Net loss $18.7M ($0.73/share) vs $9.2M loss ($0.37) in Q1 2023; operating expenses $26.8M.","Full-year 2024 commercial revenue expected at lower end of $78.5-84.5M range, implying ~57% growth.","Launched PermeaDerm biosynthetic wound matrix in US on March 23, 2024.","RECELL GO FDA decision by May 30, 2024; cashflow breakeven targeted no later than Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":11104000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228988,"accession_number":"0000950170-24-043776","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical cuts Q1 2024 revenue guidance to $11.0-$11.3M from prior $14.8-$15.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expected Q1 commercial revenue $11.0M-$11.3M vs prior guidance $14.8M-$15.6M.","Full-year 2024 revenue guidance reaffirmed at lower end of $78.5M-$84.5M.","Slower new account conversion: 73 accounts added since June 2023 vs expected 135 by March 2024.","Launched PermeaDerm in March; RECELL GO launch upcoming.","Q1 2024 earnings call scheduled for May 13, 2024 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":11104000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247606,"accession_number":"0000950170-24-018735","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%.","Full-year 2023 commercial revenue $49.8M (+46% YoY); net loss $35.4M ($1.40/share).","Q1 2024 revenue guidance $14.8-15.6M; FY2024 guidance $78.5-84.5M (57-69% growth).","Expects RECELL GO FDA launch May 31, 2024; sales team to expand to 108.","Targeting cashflow breakeven and GAAP profitability no later than Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":50143000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247605,"accession_number":"0000950170-24-003621","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"AVITA reports preliminary FY2023 revenue $49.8M (+46% YoY), signs PermeaDerm distribution deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2023 commercial revenue ~$14.1M (+50% YoY); full-year 2023 commercial revenue ~$49.8M (+46% YoY).","FY2023 gross margin ~84.5%; cash, equivalents and marketable securities ~$89.1M as of Dec 31, 2023.","FY2024 revenue guidance $78.5M–$84.5M (+57%–69% YoY); Q1 2024 guidance $14.8M–$15.6M (+42%–50% YoY).","Exclusive multi-year distribution agreement with Stedical Scientific for PermeaDerm in the US; 5-yr initial term, 50% gross margin on sales.","Completed enrollment in TONE post-market vitiligo study (109 patients); 12-month follow-up with 6-month primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265064,"accession_number":"0000950170-23-062036","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q3 commercial revenue up 51% to $13.5M; net loss $8.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $13.5M (+51% YoY); total revenue $13.6M; gross margin 84.5%.","Net loss $8.7M ($0.34 loss per share) vs $5.6M loss a year ago; operating expenses $21.0M.","Q4 2023 revenue guidance $15.3M-$16.3M (64%-73% YoY growth); full-year $51M-$53M.","Secured up to $90M debt facility; $40M drawn at closing; cash $60.1M as of Sept 30.","Expect FDA approval of RECELL GO by May 30, 2024; targeting profitability in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":35948000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265063,"accession_number":"0000950170-23-054644","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AVITA Medical settles $1M with former CEO Dr. Michael Perry over departure claims","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Settlement of $1 million, split into wage and non-wage payments, for general release of claims.","Agreement includes mutual non-disparagement clause; no admission of allegations by company.","Settlement resolves claims related to Dr. Perry's prior departure from AVITA Medical."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265062,"accession_number":"0000950170-23-053882","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"AVITA Medical secures $90M debt facility from OrbiMed; prelim Q3 revenue $13.5M (+50% YoY)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Preliminary Q3 commercial revenue $13.5M, +50% YoY from ~$9.0M; gross margin ~84.5%.","Full-year 2023 revenue guidance unchanged at $51-53M.","$40M funded at close; up to $50M more available in two tranches based on revenue thresholds.","Five-year term matures Oct 2028; OrbiMed gets warrant for 409,661 shares at $10.9847.","Management expects financing to fund growth and support reaching profitability during 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265061,"accession_number":"0000950170-23-050935","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AVITA Medical receives FDA additional info request for RECELL GO PMA; launch pushed to mid-2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed RECELL GO PMA supplement on hold for ~4-6 months pending additional info.","Review will resume 180-day cycle upon complete response, with 90 days remaining.","Implied product launch is now between May 1 and July 1, 2024.","PMA was submitted June 30, 2023 under Breakthrough Device program.","Company received notice at halfway point of the 180-day review cycle."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282261,"accession_number":"0000950170-23-041292","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AVITA Medical Q2 commercial revenue up 42% to $11.7M; raises FY2023 guidance to $51-53M; two FDA approvals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.","FDA approved RECELL for full-thickness skin defects (June 7) and vitiligo repigmentation (June 16).","FY2023 revenue guidance raised to $51-53M from prior $49-51M; Q3 guidance $13-14M.","RECELL GO PMA supplement submitted; FDA decision expected by December 27, 2023.","Cash $68.8M, no debt; gross margin guided 83-85% for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":22303000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301408,"accession_number":"0001193125-23-174497","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AVITA Medical reveals ~391K annual eligible procedures after expanded RECELL FDA approval","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Expanded FDA indication for full-thickness skin defects opens ~391,000 annual eligible procedures.","Traumatic wound market: ~127,000 procedures including degloving, crush, and avulsion.","Surgical wounds (including cancer excision) total ~264,000 eligible procedures.","Chronic wounds (DFU, VLU, pressure ulcers) account for ~128,000 annual procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301407,"accession_number":"0001193125-23-168182","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical names David O'Toole CFO; $450K salary, 150K options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David O'Toole appointed CFO effective June 15, 2023; brings 30+ years biotech/life sciences finance experience.","Annual base salary of $450,000; eligible for performance bonus up to 40% of base (max 90% combined).","Granted 150,000 stock options under 2020 Omnibus Plan vesting in 3 equal annual installments.","On termination without cause: 12 months base salary plus health benefits, unvested options accelerated for 3 months.","Most recently CFO of Opiant Pharmaceuticals (acquired by Indivior); previously CFO of Soleno Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301406,"accession_number":"0001193125-23-162334","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AVITA Medical stockholders approve 2.5M share increase in 2020 Omnibus Plan and new ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2020 Omnibus Incentive Plan increasing shares by 2.5 million.","Stockholders approved Employee Stock Purchase Plan authorizing up to 1 million shares.","All seven director nominees elected; Grant Thornton LLP ratified as auditor for FY 2023.","Advisory vote on named executive officer compensation approved: ~8.6M for, ~1.6M against.","CEO James Corbett granted options to acquire 100,000 shares; non-employee directors receive RSUs and options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301403,"accession_number":"0001193125-23-145360","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K/A","filed_at":"2023-05-16T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"AVITA Medical corrects Q1 revenue to $10.6M, net loss $9.2M in 8-K/A amendment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.6M (U.S. Dollars); net loss $9.2M, $0.37 per share for quarter ended March 31, 2023.","Original 8-K transcript erroneously included extraneous tabular data in Australian Dollars; this amendment corrects that error.","Further details available in Form 10-Q filed May 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":10550000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301405,"accession_number":"0001193125-23-143451","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"AVITA Medical Q1 commercial revenue up 40% to $10.5M; reaffirms FY guidance; CCO resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $10.5M (+40% YoY); total revenue $10.6M (+40%); gross margin 84% vs 76%.","Net loss improved to $9.2M ($0.37/share) from $9.5M ($0.38); adjusted EBITDA loss flat at $6.4M.","Cash $77.6M, no debt; reaffirms FY commercial revenue guidance of $49-51M; Q2 guidance $10.7-11.7M.","Expects FDA approval for soft tissue repair and vitiligo in June 2023; RECELL GO submission by June 30.","Erin Liberto resigned as CCO effective May 11; role discontinued. Promoted Bromley to SVP Global Sales, Garner to SVP Global Marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":10550000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301404,"accession_number":"0001193125-23-109996","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical to report Q1 2023 financial results on May 11 after market close","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Results will be released after U.S. markets close on Thursday, May 11, 2023.","Conference call scheduled for 1:30 p.m. PT (Friday, May 12, 6:30 a.m. AEST).","Webcast and dial-in details available via investor relations section of website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321227,"accession_number":"0001193125-23-080474","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"AVITA Medical appoints Robert McNamara to board, sets 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert McNamara appointed to Board of Directors effective April 1, 2023.","McNamara receives $70K annual cash, $210K initial equity, $105K annual equity (subject to shareholder approval).","McNamara has 25+ years of med-tech leadership; currently on boards of Axonics, Teknova, Xtant Medical.","2023 Annual Meeting scheduled for June 6, 2023 via live audio webcast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321226,"accession_number":"0001193125-23-076835","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AVITA Medical amends CEO James Corbett's employment agreement; severance extended, options vest on change of control","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual bonus payout moved to no later than March 15 for prior calendar year.","Option grants now provide 100% immediate vesting upon a Change in Control.","Severance period increased from 12 to 18 months for termination without cause or for good reason.","Removed change-in-control termination payments and long-distance commuting reimbursements for food/fuel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321225,"accession_number":"0001193125-23-075191","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AVITA Medical appoints Cary Vance to Board of Directors, effective April 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cary Vance appointed as non-executive director, effective April 1, 2023, serving until 2023 Annual Meeting.","Compensation: $70,000 annual cash, initial $210,000 stock grant (30% options, 70% RSUs), and $105,000 annual equity, subject to shareholder approval.","Vance has over 25 years healthcare leadership, currently President/CEO of Titan Medical; prior roles include Hansen Medical, Covidien, and GE Healthcare.","Board determined Vance meets independence standards; no material relationships or arrangements with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321224,"accession_number":"0001193125-23-064487","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AVITA Medical CEO presented at TD Cowen Health Care Conference on March 7","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Jim Corbett presented at TD Cowen 43rd Annual Health Care Conference in Boston.","A replay of the webcast will remain available on the Company's website for 30 days.","Information disclosed is preliminary, unaudited, and subject to change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321223,"accession_number":"0001193125-23-058123","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AVITA Medical holds Q4 2022 investor webinar; no new material information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Webinar held Feb 28, 2023 with CEO Jim Corbett and acting CFO Sean Ekins.","Covered highlights from Q4 2022 earnings call; no new financial data provided.","Slide deck furnished as Exhibit 99.1 but not fully available in this filing.","No specific financial results, guidance changes, or material events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321222,"accession_number":"0001193125-23-032567","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical to report Q4/FY2022 results on Feb 23, 2023, provide 2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Results due after market close on Thursday, Feb 23, 2023.","Conference call at 1:30 p.m. PT (Feb 23) / 8:30 a.m. AEDT (Feb 24).","Webcast available on ir.avitamedical.com; replay afterward.","2023 revenue guidance will be discussed on the call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321221,"accession_number":"0001193125-23-011170","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2023-01-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AVITA Medical announces departure of CFO Michael Holder and COO Kathy McGee, appoints Sean Ekins as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael Holder and COO Kathy McGee leaving Avita Medical effective Jan 19, 2023.","Sean Ekins, SVP of Finance, appointed interim CFO; company will search for permanent CFO.","COO role discontinued; product development, operations, regulatory report directly to CEO James Corbett.","Holder and McGee receive severance: 12 months base salary, health benefits, stock acceleration; McGee also gets 2022 bonus of $164,140.","Company will report Q4 2022 earnings on Feb 23, 2023, and provide revenue guidance for Q1 and full year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339337,"accession_number":"0001193125-22-309133","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AVITA Medical submits FDA PMA application for RECELL System to treat stable vitiligo","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PMA submitted to FDA to expand RECELL indication to stable vitiligo; received Breakthrough Device designation.","Pivotal trial met primary endpoint of super-superiority (p<0.025) on repigmentation success rates.","Standard FDA review timeline for PMA is 180 days; full launch anticipated January 2025 if approved.","Vitiligo affects up to 6.5M Americans (~1.3M stable); limited treatment options exist.","This PMA follows original RECELL approval for burns in September 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339336,"accession_number":"0001193125-22-304795","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Avita Medical annual meeting: all directors elected, quorum bylaw amendment fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; each received 9.2M-10.4M votes for.","Ratification of Grant Thornton as independent auditor approved (12.4M for, 224K against).","Proposal to reduce stockholder meeting quorum failed (9.6M for, 956K against; needed majority of outstanding shares).","Equity grants to directors Panaccio, Crowe, Curnock Cook, Reed (RSUs+options worth $87.5K+$37.5K each) and CEO Corbett (options worth $1M) approved.","Non-binding say-on-pay advisory vote passed (7.8M for, 2.4M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339335,"accession_number":"0001193125-22-283537","cik":1762303,"company_name":"AVITA Medical, Inc.","ticker":"RCEL","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.","Net loss $5.6M ($0.22/sh); cash $88.2M, no debt.","Soft-tissue repair trial met co-primary endpoints; vitiligo trial achieved super-superiority.","FY 2022 commercial revenue guidance raised to $33-34M from $30M.","Japan MHLW grants RECELL approval; partner COSMOTEC launching in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":24966000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":129262096.51764706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-14T23:59:59+00:00|339335"}